norspan buprenorphine 40 micrograms/h transdermal drug delivery system sachet
mundipharma pty ltd - buprenorphine, quantity: 40 mg - drug delivery system, transdermal - excipient ingredients: levulinic acid; oleyl oleate; povidone; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; heptane; aluminium acetylacetonate - norspan patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. norspan patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. norspan patches are not indicated as an as-needed (prn) analgesia.
norspan buprenorphine 30 micrograms/h transdermal drug delivery system sachet
mundipharma pty ltd - buprenorphine, quantity: 30 mg - drug delivery system, transdermal - excipient ingredients: levulinic acid; oleyl oleate; povidone; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; heptane; aluminium acetylacetonate - norspan patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. norspan patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. norspan patches are not indicated as an as-needed (prn) analgesia.
norspan buprenorphine 25 micrograms/h transdermal drug delivery system sachet
mundipharma pty ltd - buprenorphine, quantity: 25 mg - drug delivery system, transdermal - excipient ingredients: levulinic acid; oleyl oleate; povidone; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; heptane; aluminium acetylacetonate - norspan patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. norspan patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. norspan patches are not indicated as an as-needed (prn) analgesia.
norspan buprenorphine 15 micrograms/h transdermal drug delivery system sachet
mundipharma pty ltd - buprenorphine, quantity: 15 mg - drug delivery system, transdermal - excipient ingredients: levulinic acid; oleyl oleate; povidone; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; heptane; aluminium acetylacetonate - norspan patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. norspan patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. norspan patches are not indicated as an as-needed (prn) analgesia.
norspan buprenorphine 20microgram/hour transdermal drug delivery system sachet
mundipharma pty ltd - buprenorphine, quantity: 20 mg - drug delivery system, transdermal - excipient ingredients: oleyl oleate; povidone; levulinic acid; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane - norspan patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. norspan patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. norspan patches are not indicated as an as-needed (prn) analgesia.
norspan buprenorphine 10microgram/hour transdermal drug delivery system sachet
mundipharma pty ltd - buprenorphine, quantity: 10 mg - drug delivery system, transdermal - excipient ingredients: oleyl oleate; povidone; levulinic acid; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; heptane; aluminium acetylacetonate - norspan patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. norspan patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. norspan patches are not indicated as an as-needed (prn) analgesia.
norspan buprenorphine 5microgram/hour transdermal drug delivery system sachet
mundipharma pty ltd - buprenorphine, quantity: 5 mg - drug delivery system, transdermal - excipient ingredients: levulinic acid; oleyl oleate; povidone; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; heptane; aluminium acetylacetonate - norspan patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. norspan patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. norspan patches are not indicated as an as-needed (prn) analgesia.
norspan
mundipharma pty ltd - buprenorphine -
norspan
mundipharma new zealand ltd - buprenorphine 10mg; ; - transdermal patch - 10 mg - active: buprenorphine 10mg excipient: polyacrylate. durotak 387.2054 and durotak 387.2051 levulinic acid oleyl oleate povidone - management of moderate to severe pain.
norspan
mundipharma new zealand ltd - buprenorphine 20mg; ; - transdermal patch - 20 mg - active: buprenorphine 20mg excipient: polyacrylate. durotak 387.2054 and durotak 387.2051 levulinic acid oleyl oleate povidone - management of moderate to severe pain.